Key facts
- This page summarizes Elise Brownell's Form 4 filing for IMPACT BIOMEDICAL INC. (IBO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Nov 2026, 17:50.
Elise Brownell - 07 Oct 2026 Form 4 Insider Report for IMPACT BIOMEDICAL INC. (IBO)
- Reporting relationship
- Director
- Issuer ticker
- IBO
- Reported as of
- 07 Oct 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Nov 2026, 17:50:28 UTC
- Prior SEC filing
- 16 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elise Brownell
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Elise Brownell filed Form 4 for IMPACT BIOMEDICAL INC. (IBO) on 05 Nov 2026.
Change
- Previous filing in this sequence was filed on 16 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002008042
Primary reporting owner
Brownell Elise
- Relationship
- Director
- Address
- 275 WIREGRASS PKWY, HENRIETTA
- Signature
- /s/ Elise Brownell
- Signature date
- 05 Nov 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IBO
transaction
Common Stock
Award
- Transaction value
- Shares
- -4,170
- Change %
- -11%
- Price
- $4.54*
- Shares after
- 32,112
- Date
- 07 Oct 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Reward pursuant to Impact BioMedical Inc.'s 2023 Employee, Director and Consultant Equity Incentive Plan